Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | short review

The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma

verfasst von: Ewald Wöll, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Cancers of the upper gastrointestinal tract and pancreas are still among the most devastating neoplastic diseases. Cure is achieved only if the diagnosis is made at an early stage. Given the low incidence of these neoplasias in the Western world, surveillance programs are not available and practicable; therefore, most of the patients suffering from these cancers are diagnosed in a locally advanced or metastatic stage and treated in a palliative setting. Treatment response and duration is crucial and maintenance strategies are therefore desperately warranted. Molecular targeted therapies with a low toxicity profile could make ideal proponents for this attempt. This short review summarizes the relevant trials investigating maintenance treatments in esophageal cancer, gastric cancer and pancreatic cancer.
Literatur
1.
Zurück zum Zitat Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5(2):229–35.PubMedCrossRef Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5(2):229–35.PubMedCrossRef
2.
Zurück zum Zitat Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119–27.PubMedCrossRef Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119–27.PubMedCrossRef
3.
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
4.
Zurück zum Zitat Hegewisch-Becker S, et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES. J Clin Oncol. 2012;30(suppl; abstr 4065). Hegewisch-Becker S, et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES. J Clin Oncol. 2012;30(suppl; abstr 4065).
5.
Zurück zum Zitat Waddell TS, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30:(suppl; abstr LBA4000) Waddell TS, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30:(suppl; abstr LBA4000)
6.
Zurück zum Zitat Lordick F, et al. Cetuximab in combination with capecitabine and cisplatin as first line treatment in advanced gastric cancer: randomized controlled phase III EXPAND study. ESMO 2012:abstr LBA3. Lordick F, et al. Cetuximab in combination with capecitabine and cisplatin as first line treatment in advanced gastric cancer: randomized controlled phase III EXPAND study. ESMO 2012:abstr LBA3.
7.
Zurück zum Zitat Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedCrossRef Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedCrossRef
8.
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.PubMedCrossRef Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.PubMedCrossRef
9.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.PubMedCrossRef Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.PubMedCrossRef
10.
Zurück zum Zitat Reni M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: clinical and translational results of a phase II randomized trial. J Clin Oncol. 2012;30:(suppl; abstr 4017). Reni M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: clinical and translational results of a phase II randomized trial. J Clin Oncol. 2012;30:(suppl; abstr 4017).
Metadaten
Titel
The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma
verfasst von
Ewald Wöll, MD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0073-0

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe